CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,235 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05365750
NCT05365750N/ACompleted

COVID-19 Antibody and Reinfection Study

Kaiser Permanente·observational·Posted May 9, 2022·Updated Sep 18, 2025

In Brief

An observational study for COVID-19 Testing. Completed, enrolled 4,235 participants across 1 site.

Detailed Summary

The goal of this study is to establish a cohort of Kaiser Permanente Colorado (KPCO) members who have and have not had COVID-19 infection for serial antibody testing and PCR testing to: 1. Quantify antibody titers among participants over 9 months. 2. Determine the rates of asymptomatic, mild, and severe recurrent infection among participants with prior COVID-19. 3. Examine association between antibody titer levels and risk of recurrent infection using a case control analysis nested in the cohort.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedMay 9, 2022
Enrollment StartJun 15, 2020
Primary CompletionMar 30, 2023
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.1 years ago